Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127374 | 0.68 | FADS1 (0.46) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL29615409 | 0.68 | FADS1 (0.46) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL12266517 | 0.67 | LMNA (0.60) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL31393644 | 0.64 | F2RL3 (0.42) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL30110720 | 0.63 | CYP1A1 (0.41) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL17329014 | 0.63 | CYP1A1 (0.41) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL29210400 | 0.63 | F2RL3 (0.47) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL15124778 | 0.61 | LMNA (0.44) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL30576347 | 0.61 | LMNA (0.44) | LMNACYP3A4MAPTAPEX1MAPK1 | |
| SCHEMBL21295644 | 0.61 | KDM4E (0.42) | LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | claimed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | claimed |
| US-6414149-B1 | TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS | PFIZER INC. | 2002-07-02 | — | — | US | claimed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | claimed |
| US-6936600-B2 | Sorbitol dehrydrogenase inhibitors | PFIZER INC (US) | 2005-08-30 | — | — | US | disclosed |
| US-6869943-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | disclosed |
| US-6660740-B1 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-12-09 | — | — | US | disclosed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | disclosed |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2003-04-03 | — | — | US | disclosed |
| US-6414149-B1 | TREATING DIABETES, TREATING OR PREVENTING DIABETIC COMPLICATIONS | PFIZER INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1185275-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000059510-A1 | AMINOPYRIMIDINES AS SORBITOL DEHYDROGENASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020578-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | LMNA 2122/4885CYP3A4 2971/4885MAPT 2491/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | LMNA 1870/4885CYP3A4 3451/4885MAPT 2399/4885 |
| US-20030065179-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | LMNA 1870/4885CYP3A4 3451/4885MAPT 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.